Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Mastering the Art of Expertise in Thread Lift Procedures: From Pioneer to Perfector Business
  • Patil Automation Secures ₹8.25 Crore Order for Automotive Robotics Systems Business
  • Interim Budget 2024: IMS Ghaziabad (University Courses Campus)’s Perspective on Catalyzing Research, Innovation, and Entrepreneurship Finance
  • Kay Cee Energy and Infra Limited annlounced FY25 results Business
  • JetSynthesys acquires franchise rights of the ‘Ratnagiri Jets’ in Maharashtra Premier League 2023 Business
  • AIS Design Olympiad (ADO) 7.0 Crowns National Winners Business
  • Global IP authority & former top IAS officer Dr Pushpendra Rai joins the Advisory Board of the Centre for Innovation in Public Policy (CIPP) Business
  • Indian Chemical Council aims at making India Resilient in Chemical Logistics Operations with Nicer Globe Business

ISSAR Pharma Announces Out-Licensing of Its Peptide-Based NCEs

Posted on April 29, 2021 By

ISSAR Pharma, the only company in India which focuses on the research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, opening opportunities for fruitful partnerships.

Hyderabad (Telangana) [India], April 29: ISSAR Pharmaceuticals, the Pioneer in Peptide Technology and peptide drug innovation, has decided to license out their peptide-based New Chemical Entities (NCEs), with pre-IND filing and US Patent. The potential collaboration would help ISSAR Pharmaceuticals in their goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population and making them affordable and accessible for better health outcomes.

ISSAR Pharmaceuticals exclusively focuses on peptide technology-based research and development of New Chemical Entities (NCE) for various unmet medical needs to improve the quality of life. ISSAR uses Solid-phase peptide synthesis as the technology of choice and has the capability to synthesize custom peptides, API peptides, and cosmetic peptides at all scales within a short duration. With an emphasis on quality, safety, and innovation, ISSAR has demonstrated the ability to move products from conceptualisation to commercialisation of peptide molecules at all stages. ISSAR has several patents for potential life-changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology, and diseases of bones and joints.

“We take pride in being India’s first-ever company to conduct phase-1 clinical trials and launch the first-ever indigenous peptide drug, Melgain in the market for the treatment of Vitiligo in 2004”, informs Mr. Ramakrishna Reddy Isanaka, the founder of ISSAR. ISSAR’s

FDA- compliant state-of-the-art manufacturing facility of 62000 sq. ft., is purely into peptide manufacturing technology, located in Genome Valley, Hyderabad, India. In addition to its experience in R&D, ISSAR is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing the highest standards of purity of up to 99.5% by continued process optimization.

With over 25 years of experience and a prime focus in Research and Development, ISSAR’s dedicated team of experts is proud to have developed India’s first-ever peptide molecule, Melgain for the treatment of Vitiligo in 2004, which is now introduced as Novoskin® with improved properties and effectiveness. ISSAR’s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first-ever peptide drug in the world for the treatment of burn wounds and microbial infections.

ISSAR developed molecules for prevalent conditions in the Western world such as Inflammatory Bowel Diseases (IBD), Psoriasis, and Sepsis. Recently, an NCE for the treatment of burn wounds (Xylentra) was licensed to Viatris, formerly known as Mylan Laboratories, the USA in 2020.

ISSAR Pharmaceuticals was founded by Mr. Ramakrishna Reddy Isanaka in 1995 with a vision to be a global leader in peptide drug discovery for improving patients’ quality of life. Before starting ISSAR Pharmaceutical, Mr.Isanaka was the promoter and director of Shantha Biotechnics in the 1980s, at a time when Biotechnology was new to India.

His efforts in research and development led to the advancement of ISSAR Pharma as the first-ever company in India to conduct Phase-I Clinical Trials in the year 1995. Today, he has over 25 years of experience in the development of NCEs with 2 successfully commercialized products, 7 plus patents to his credit, and over 6 commercially viable products under development.

https://issar.co.in/

English, Health, Press Release Tags:ISSARPharma, PeptidebasedNCEs, PNN

Post navigation

Previous Post: Glimpse up the world @worldwithmaria
Next Post: Indian Furniture Rental Industry – Market Size, Growth & Scope

Related Posts

  • VPN IBE Awards 2025 honor trailblazers with style Press Release
  • CKOSMIC Health City: Long-Term Support for Weight Loss Health
  • St. George’s University’s Indian Medical Students Secure Us Residencies Press Release
  • Glimpse up the world @worldwithmaria English
  • A New Era for Cuesports: WPA World Junior Heyball Championship 2024 Concludes in Bangalore Press Release
  • FREOSSI Wound Healing Spray with Curcumin: Supporting Everyday Wound Care for Pets Health

Recent Posts

  • Pan IIT Alumni India Welcomes PM Modi’s Visit to IIT Kharagpur for Platinum Jubilee Celebrations
  • ‘Plast Pack 2026’ Begins with Bhoomi Pujan; Mega Plastic Industry Expo to Commence on November 27
  • The Ambiente Brings Luxury Handmade Rugs and Carpets Online to Homes Across India
  • ‘Mere Mahavir 3.1 – Mahavir Nirvana Katha’ Concludes on a Grand Spiritual Note at Bharat Mandapam
  • HydraSure’s Gen Z Team Turns GTA VI Launch Day Into a Giveaway – Planned and Live in 24 Hours

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Renowned DJ Ganesh gets applauded by Karan Johar for setting the vibe for his 50th birthday bash! Lifestyle
  • Dr. Deepika Krishna – India’s Leading Voice in Longevity, Wellness & Preventive Healthcare Business
  • Sharul Channa, Singapore’s Leading Stand-Up Comic, Teams Up with Renowned Saree Brand, Suta for Women’s Day India Tour Entertainment
  • Avvanz Tackles Employee Screening Challenges: Affordable, Compliant, and Comprehensive Background Checks Now Available In India Business
  • Golden Globes 2026 Delivers A Glorious Win — And A Few Familiar Eye-Rolls Entertainment
  • Surat-based Maiora Diamonds – Lab Grown Diamond Jewellery Brand to expand across India Lifestyle
  • Designing the Language That Shapes What the World Understands Education
  • Sanddoge The most expensive and most luxury meme token of the 2025 Finance

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme